Abiosciences

Abiosciences, founded in 2018, is a life science technology company with a global perspective. Driven by innovation based on cutting-edge science, we are committed to accelerating groundbreaking discoveries and developing first-in-class therapeutic drugs. Leveraging our research strengths and self-developed single-cell big data platform, we create precise human disease cell atlases, providing new insights for identifying and validating novel targets and biomarkers, and assisting our partners in developing next-generation breakthrough therapies and diagnostic methods. Since its establishment, the company has quickly attracted a group of high-level entrepreneurial talents, gathered an efficient senior leadership team, and formed a world-class R&D team. Currently, independent R&D centers have been set up in Beijing, Shanghai, and San Francisco, with strategic layouts focused on the international market. Our antibody R&D center concentrates on the study of innate immunity and tumor microenvironment regulation. Based on our innovative drug development platform, we analyze the druggability potential of targets from various dimensions such as specificity and safety, and have discovered multiple innovative drug targets. By integrating cutting-edge antibody technologies with AI protein engineering, we have established a fast track from target discovery to new drug development, and some targets have already reached strategic cooperation agreements with internationally renowned pharmaceutical companies.